
BFRA on NASDAQ | Today's Change | Volume | 52 Week Range (Low/Hi) | Market Cap |
12.75US | 0.00/0.00% | 0 | 11.04 / 17.98 | 284.53 M |
Contact Information
Biofrontera AG
Headquarters:Hemmelrather Weg 201,
Leverkusen, North Rhine-Westphalia
Germany, 51377
Tel: 49-214-87632-0
Email: Send a message
Website: Visit website
For more information...
Lead: Robert ThaemlitzFeb 28, 2019 - 1:00 PM PST |
Corporate Presentation - Los Angeles |
Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.
Prof. Dr. Rer. Nat. Hermann Lübbert - Chief Executive Officer
Thomas Schaffer - Chief Financial Officer
Christoph Dünwald - Chief Compliance Officer
Ulrich Granzer, PhD. - Chairman
Jürgen Baumann - Vice Chairman of the Board
John Borer III, J.D. - Supervisory Board Member
Kevin Weber - Supervisory Board Member
Reinhard Eyring - Supervisory Board Member
Hansjörg Plaggemars - Supervisory Board Member

Stock Information
Events
Feb 28, 2019 - 1:00 PM PST |
Corporate Presentation - Los Angeles |
Press Releases
Company Overview
Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.
Management
Prof. Dr. Rer. Nat. Hermann Lübbert - Chief Executive Officer
Thomas Schaffer - Chief Financial Officer
Christoph Dünwald - Chief Compliance Officer
Board of Directors
Ulrich Granzer, PhD. - Chairman
Jürgen Baumann - Vice Chairman of the Board
John Borer III, J.D. - Supervisory Board Member
Kevin Weber - Supervisory Board Member
Reinhard Eyring - Supervisory Board Member
Hansjörg Plaggemars - Supervisory Board Member
Contact Information
Hemmelrather Weg 201,
Leverkusen, North Rhine-Westphalia
51377, Germany
Telephone: 49-214-87632-0
Email: Send a message
Website: Visit website